Rich countries study the diseases that afflict their citizens. For the ailments of the poor world, they offer sympathy and perhaps a few bucks. That explains the plight of malaria. An effort to break out of that bind failed recently when a group of the leading pharmaceutical companies turned down a proposal to establish a consortium of public and private organizations for research on malaria and other tropical diseases.